Interleukin-9 (IL-9) stimulates the proliferation of mast cells and lymphocytes. In the present study, we showed that IL-9 induced a transient phosphorylation of MEK, ERK2 and p90/RSK in murine lymphoid and mast cell lines. ERK2 in vitro kinase activity was also increased upon IL-9 stimulation. Similar results were obtained with IL-4, which had not been previously reported to activate these kinases in hematopoietic cells. Analysis of IL-9 receptor mutants showed that activation of the pathway was correlated with proliferation and with phosphorylation of the adaptor protein SHC, but not IRS2 or GAB2. The MEK inhibitor PD98059 reduced the mitogenic response to IL-4 and IL-9. In addition, expression of a dominant-negative RAS variant blocked ERK phosphorylation and significantly decreased Ba/F3 cell growth in the presence of IL-9, but did not affect expression of pim-1, a STAT target gene. In summary, these results indicate that IL-9 can transiently activate the mitogen-activated protein kinase pathway, which contributes to growth stimulation of hematopoietic cell lines.
Introduction
The mitogen-activated protein kinase (MAPK) cascade contributes to signal transduction by most membrane receptors, including those of growth factors, cytokines, chemokines and polypeptidic hormones (Robinson and Cobb, 1997) . This pathway is usually initiated by the activation of tyrosine kinases and binding of adaptor proteins to the receptor, through the interaction of phosphorylated tyrosines with SH2 or PTB domains. This protein scaffold, which frequently includes SHC and GAB, recruits the GRB2/SOS complex to plasma membrane, allowing SOS to favor the exchange of GDP for GTP on RAS (Robinson and Cobb, 1997 ). GTPbound RAS then binds to the RAF kinase, which phosphorylates MEK, an MAPK kinase. MEK1 or MEK2 activates ERK1 and ERK2 by phosphorylating both a threonine and a tyrosine residue. The latter kinases regulate various transcription factors either directly or via the p90/RSK kinase (Frodin and Gammeltoft, 1999) . They play an important role in the control of cell proliferation, differentiation and apoptosis (Robinson and Cobb, 1997) . Based on binding of labeled GTP to RAS, and on ERK in vitro kinase assays, several reports have suggested that interleukin-9 (IL-9) and IL-4 do not use this pathway (Satoh et al., 1991; Duronio et al., 1992; Miyazawa et al., 1992; Welham et al., 1994 Welham et al., , 1995 Pruett et al., 1995; Gomez et al., 1996; Louahed et al., 1999) .
IL-9 and IL-4 have been implicated in immune responses against extracellular parasites and in asthma disease (Nicolaides et al., 1997; Nelms et al., 1999; Richard et al., 2000) . In vitro, these pleiotropic cytokines stimulate the growth of mast cells (Renauld et al., 1995; Renauld and Van Snick, 1998; Nelms et al., 1999) . IL-9 transgenic mice develop mastocytosis, and expansion of B1 lymphocytes and eosinophils (Renauld and Van Snick, 1998; Temann et al., 1998; Vink et al., 1999; Louahed et al., 2001) . A striking characteristic of IL-9-induced proliferation is its association with tumoral transformation. In vitro, IL-9 induces the proliferation of murine T lymphoma and myeloid leukemia cells, but not their normal counterpart (Renauld et al., 1995; Lemoli et al., 1996) . In vivo, IL-9 overexpression does not induce T-cell hyperplasia, but IL-9 transgenic mice are highly susceptible to T-cell lymphoma development after administration of low doses of mutagens or irradiation (Renauld et al., 1994 (Renauld et al., , 1995 .
In cells of hematopoietic origin, IL-4 and IL-9 interact with a specific receptor chain (IL-4Ra and IL-9R, respectively) and the gc receptor subunit, which is also shared by IL-2, IL-7 and IL-15 (Demoulin and Renauld, 1998; Nelms et al., 1999) . Two tyrosine kinases, JAK1 and JAK3, are associated with the specific receptor and gc, respectively. JAK kinases phosphorylate receptor tyrosine residues that act as docking sites for signaling proteins containing SH2 or PTB domains, such as STAT transcription factors and insulin receptor substrate (IRS) adaptor proteins. IL-4 activates mainly STAT6 and, in some cell types, STAT3 (Rolling et al., 1996) . IL-9 activates STAT1, STAT3 and STAT5 (Demoulin et al., 1996) . These factors have been shown to play a key role in many IL-4 and IL-9 activities (Kaplan et al., 1996; Demoulin et al., 1999 Demoulin et al., , 2000b . In addition, IRS1 and IRS2 are required for mitogenic responses (Keegan et al., 1994; Yin et al., 1995; Zhu et al., 1997; Demoulin et al., 2000a; Xiao et al., 2002) .
In this study, we show that IL-9 and IL-4 induced a transient phosphorylation and activation of ERK in murine hematopoietic cell lines. Phosphorylation of SHC, MEK1/2 and p90/RSK was also found. This pathway played a role in growth stimulation by IL-9.
Results
Activation of the MAPK pathway by IL-9 in lymphoid and mast cell lines ERK1 and ERK2 activity is controlled by double phosphorylation of a TEY motif in the activation loop (Miyata and Nishida, 1999) . To analyse the effect of IL-4 and IL-9 on MAPK, we performed Western blots using antibodies specific for this phosphorylated regulatory site. Both cytokines induced a transient p42/ ERK2 phosphorylation in the T helper cell line TS1 (Figure 1) . A significant signal was observed with as low as 100 pg/ml of IL-4 or 10 U/ml (7250 pg/ml) of IL-9 (data not shown). In the mast cell line MC9, both p44/ ERK1 and p42/ERK2 were phosphorylated to a comparable extent in cells treated with IL-9 or IL-3 for 10 min. Human IL-9 had a more modest effect in two murine hematopoietic cell lines transfected with the human IL-9R, Ba/F3 and 32D (Figure 1 ). It was completely blocked by anti-IL-9R antibodies (data not shown). In all cell types tested, ERK phosphorylation in response to IL-4 or IL-9 was transient, unlike IL-3, which induced a more sustained ERK phosphorylation (not shown).
To confirm that ERK2 was activated by IL-9 and IL-4, we performed an in vitro kinase assay using myelin basic protein as a substrate, after immunoprecipitation of the kinase from TS1 cells. As shown in Figure 2a , stimulation with either cytokine increased ERK2 activity up to five times, which was in the same range as the effect of IL-2 on other T cell lines (not shown). In vivo ERK substrates include p90/RSK, the 90-kDa ribosomal S6 kinase (Frodin and Gammeltoft, 1999) . RSK phosphorylation by ERK results in autophosphorylation of RSK at serine 381, which is required for activation of all three RSK isoforms. Using antibodies directed against this regulatory site, we found that it was phosphorylated in response to IL-4 and IL-9 in TS1 cells (Figure 2b ), as expected if MAPKs are activated in these cells.
We next asked whether ERK2 activation in these cell lines was mediated by MEK (MEK1 or MEK2), as in other models (Robinson and Cobb, 1997) . Like ERK2 and RSK, MEK was phosphorylated in response to IL-4 and IL-9, as judged from the Western blots presented in Figure 3a . Pretreatment of cells with the MEK inhibitor PD98059 blocked phosphorylation of ERK in response to both cytokines ( Figure 3b) . As a control, we showed that PD98059 had no effect on STAT3 tyrosinephosphorylation, which depends on JAK kinases. Taken together, these experiments showed that IL-9 and IL-4 trigger a classical MEK-ERK-RSK cascade in lymphoid and mast cell lines.
A role for the MAPK pathway in mitogenesis stimulation by IL-9
To further investigate the role of this cascade, we analysed the effect of PD98059 on the proliferation of TS1, MC9 and Ba/F3, which are factor-dependent cell lines. As shown in Figure 3c , this compound significantly inhibited thymidine incorporation upon stimulation with IL-4 and IL-9. MC9 cells were more sensitive to PD98059, the IC50 being about 2 mm for IL-4-and Figure 1 ERK phosphorylation in response to IL-9. The indicated IL-9-dependent cell lines were washed, starved for 6 h and stimulated with IL-9 (100 U/ml) or IL-4 (10 ng/ml). Western blots were performed using phospho-specific antibodies directed against ERK1/2 (phospho-Thr202/phospho-Tyr204) or STAT3 (phosphoTyr705), or anti-ERK2 antibody, as described in Materials and methods. 32D and Ba/F3 cells that were transfected with the human IL-9R were stimulated for 15 min with human IL-9 or murine IL-3 (both at 500 U/ml). All blots were reprobed with antiactin, which confirmed that equivalent amounts of protein were present in each lane (not shown) IL-9-treated cells. This is consistent with published concentrations required for MEK inhibition (Gingras et al., 2000) .
Cells cultured in the presence of IL-3 were less sensitive to PD98059 treatment, in agreement with reports showing that RAS activation is not mandatory for proliferation of Ba/F3 cells in response to IL-3 (Terada et al., 1995; Louahed et al., 1999) . We took advantage of this observation and performed a stable transfection of a dominant-negative RAS into Ba/F3-hIL9R cells cultured in the presence of IL-3. We used M-RAS asn27, a mutated RAS isoform that exerts a dominant-negative effect on MAPK activation in Ba/F3 cells (Louahed et al., 1999, and unpublished results) . We obtained clones expressing detectable amounts of wildtype or dominant-negative M-RAS (Figure 4a ). Expression of the dominant-negative construct abolished ERK1/2 phosphorylation by IL-9, but did not affect STAT3 or STAT5 phosphorylation (Figure 4b ). M-RAS asn27 -but not wild-type M-RAS -significantly decreased growth in the presence of IL-9 ( Figure 4c ). Neither PD98059 nor dominant-negative RAS affected Ba/F3 cell survival in the presence of IL-9 (data not shown).
Expression of the STAT5-target gene pim-1, which is upregulated by IL-9 (Demoulin et al., 2000b) , was reported to be sufficient to promote Ba/F3 cell growth (Nosaka et al., 1999 ). Therefore, we tested whether MAPK inhibition could decrease pim-1 expression. As shown in the Northern blot presented in Figure 5 , treatment of cells with up to 80 mm of PD98059 or expression of dominant-negative M-RAS did not affect pim-1 induction by IL-9. Our data thus indicated that the MAPK pathway contributes to IL-9-mediated proliferation independently of the previously described STAT5/pim-1 pathway.
ERK and SHC phosphorylation are correlated in IL-9-stimulated TS1 cells SOS, a protein that is found associated to the adaptor GRB2, is a major GTP-exchange factor for RAS. Several scaffolding proteins, including IRS, SHC and GAB, have been implicated in the recruitment of the GRB2/SOS complex to cytokine receptors (Robinson and Cobb, 1997; Gu et al., 1998; Nelms et al., 1999) . IRS1/2, which is phosphorylated in stimulated TS1 and Ba/F3 cells (Yin et al., 1995; Demoulin et al., 1996; Zhu et al., 1997) , is unlikely to be required in this process, since ERK is activated by IL-9 in 32D cells (Figure 1 ), which lack IRS expression (Demoulin et al., 2000a) . GAB2 is highly expressed in Ba/F3 and hemopoietic cells (Gu et al., 1998) , but its role in IL-9 signaling has not been studied so far. One report showed that IL-4 does not induce GAB2 phosphorylation in T cells (Gadina et al., 2000) . In our model, the immunoprecipitation experiments presented in Figure 6 show that GAB2 was phosphorylated in response to IL-3, but not to IL-4 and IL-9. In contrast, phosphorylation of SHC was reproducibly increased by these cytokines after 10 min of treatment, and was maximal after 30 min. Interestingly, at this later time point, we observed the co-precipitation of phosphorylated proteins of about 145 kDa, as reported by others (Crowley et al., 1996) .
To delineate the IL-9R region required for ERK2 activation, we transfected wild-type and truncated human IL-9 receptors in TS1 cells. Human IL-9, which does not bind to the endogenous murine IL-9R, recapitulated the effect of murine IL-9 in cells transfected with the human wild-type receptor (Figure 7) . Truncation of the receptor after 98 cytoplasmic amino acids (IC98), which removed the docking site for STAT transcription factors (tyrosine 116) (Demoulin et al., 1996) , had no effect on ERK2 phosphorylation by human IL-9, but almost abolished STAT3 phosphorylation (Figure 7a ). Further deletion of 54 amino acids (IC44) reduced ERK2 phosphorylation more than three times. Similar results were obtained for SHC phosphorylation (Figure 7b ). IRS2 phosphorylation was not affected by either deletion, in agreement with an earlier report (Zhu et al., 1997) . Thus, SHC and ERK2 phosphorylations by IL-9 were correlated in TS1 cells, and largely depended on the 44-98 IL-9R region. Interestingly, this domain is devoid of tyrosines. ) cells were washed, starved for 6 h and stimulated with IL-4 (10 ng/ml) of IL-9 (500 U/ml) for 10 min. ERK2 was immunoprecipitated as described in Materials and methods. Its activity was assessed in the presence of g- We analysed the effect of receptor deletions on cell proliferation. TS1-IC98 cells were less sensitive to human IL-9 than cells expressing the wild-type receptor (Figure 7c) . Similar results were obtained with Y116F-mutated receptor (not shown), suggesting that the STAT-binding site plays a role in TS1 proliferation. Mitogenicity in the presence of high IL-9 doses was not significantly affected in TS1-IC98, in contrast to TS1-IC44, indicating that the 44-98 region of the receptor contributed to IL-9-driven cell growth. These results are consistent with a role for both STAT factors and ERK kinases in proliferation.
Discussion
Here, we demonstrate that IL-9 can activate the MAPK pathway in several cell lines of lymphoid and hematopoietic origin. We observed a cytokine-dependent phosphorylation of SHC, MEK1/2, ERK2 and p90/ RSK. The inhibitory effect of a M-RAS dominantnegative protein indicates that a RAS isoform is involved. Our data also suggest that IL-4 activates the same pathway. The protein scaffold that links the IL-9R to MAPK activation is not fully identified. IRS2, which is an important mediator of signaling by both IL-4 and IL-9, was not required for ERK activation, which occurred in IRS-deficient 32D cells. In our receptor mutation analysis, IRS2 phosphorylation, which depends on the proximal region of the receptor cytoplasmic part (Zhu et al., 1997) , was poorly correlated with ERK phosphorylation. In line with these results, MAPK activation by insulin was disconnected from IRS2 function (Pruett et al., 1995) . By contrast, ERK and SHC activations depended on the same receptor region in TS1 cells. This region of the receptor lacks tyrosines, suggesting that SHC may be recruited indirectly by the IL-9 receptor, unlike the IL-4 receptor, which harbors a typical NPXY docking site for the PTB domain of SHC (Nelms et al., 1999) . SHC is frequently found associated with GAB2. However, we did not observe any GAB2 phosphorylation upon IL-4 or IL-9 stimulation.
The phosphorylation kinetics of SHC and ERK differed strikingly, ERK phosphorylation peaking before SHC. Similar to what was suggested for many cytokines in previous studies, it is likely that the modest, but significant, phosphorylation of SHC observed after 10 min contributes to MAPK activation by IL-4 and IL-9. After 30 min, SHC phosphorylation was further increased, whereas ERK phosphorylation decreased. It is possible that MAPK activation in our model requires another signaling molecule, the activation of which determines the kinetics of ERK phosphorylation. In this respect, we observed that the phosphatidylinositol-3 kinase inhibitor Ly294002 decreased ERK phosphorylation mediated by IL-9 (data not shown), suggesting the involvement of that kinase, which seems to be transiently activated by IL-9 (Demoulin et al., 2000a) . Alternatively, SHC could be uncoupled from the MAPK pathway after 30 min. Several proteins that negatively regulate RAS/MAPK activation, such as FRIP and SHIP, have been reported to be activated by IL-4 (Nelms et al., 1999). We observed co-precipitation of phosphorylated 145-kDa proteins with SHC in TS1 cells stimulated with IL-4 and IL-9 for 30 min. Some of these bands were recognized by anti-SHIP antibodies (data not shown). SHIP is an inositol 5 0 -phosphatase that negatively regulates the phosphatidylinositol-3 kinase and the MAPK pathways (Rohrschneider et al., 2000) . Other phosphatases might also be involved. Further experiments should be carried out to identify the mechanism that underlies the transient nature of ERK activation by these cytokines.
Our results contrast with a large number of studies that failed to detect any activation of components of the MAPK cascade in similar cell lines (Satoh et al., 1991; Duronio et al., 1992; Welham et al., 1994 Welham et al., , 1995 Pruett et al., 1995; Gomez et al., 1996) . Differences in the cell lines used in these reports fall short from explaining this discrepancy. RAS activation by IL-4 had not been observed in TS1, MC9 and Ba/F3 (Satoh et al., 1991; Duronio et al., 1992; Gomez et al., 1996) . We also failed to demonstrate RAS-GTP association in Ba/F3-hIL9R stimulated with IL-9 (Louahed et al., 1999) . These studies measured loading of labeled GTP onto RAS to test activation of the protein, an assay that is poorly sensitive and might lead to underestimation of low-level RAS activation (de Rooij and Bos, 1997) . In addition, we cannot exclude that activation of the pathway in our model depends on a RAS family member distinct from those that have been tested in these reports. Several studies also failed to detect ERK activation by IL-4 after immunoprecipitation followed by an in vitro kinase assay, or an antiphosphotyrosine Western blot (Welham et al., 1994; Pruett et al., 1995) . These methods are highly dependent on the antibodies used, and are generally less sensitive than the direct Western blot approach we used. This might explain that the effect of IL-4 and IL-9 has been overlooked, at least in cells where it is quite modest, as in 32D and Ba/F3. We could not detect ERK phosphorylation in IL-9-treated Mo/7e cells (not shown), in agreement with Miyazawa et al. (1992) . Besides these negative results, phosphorylation of SHC in response to IL-4 has been reported in two hematopoietic cell lines: 32D and WEHI-231, in line with our results (Zamorano and Keegan, 1998; Nelms et al., 1999; Gingras et al., 2000) . Nevertheless, ERK activation had not been tested in these reports.
Based on three lines of evidence, our data suggest that ERK plays a role in proliferation mediated by IL-9. First, the specific MEK inhibitor PD98059 partially but significantly decreased proliferation of IL-9-stimulated cells. Second, transfection of a dominant-negative M-RAS variant had the same effect. Finally, using mutated IL-9 receptors, we showed that ERK phosphorylation and cell growth stimulation were correlated. In TS1 cells, ERK phosphorylation largely depended on the 44-98 IL-9R region, which was required for maximal proliferation. Our data contrast with studies performed with fibroblasts, which proliferate only if ERK activation is sustained (Murphy et al., 2002) .
Results were also consistent with a role of STAT factors and IRS2 in cell growth, as suggested by our previous reports (Demoulin et al., 2000a, b) . Deletion of The phosphorylation of STAT3, STAT5 and ERK was tested in response to human IL-9 after 10 min (100 U/ml). (c) Thymidine incorporation after 3 days in the presence of control medium, human IL-9 or murine IL-3 (100 U/ml) was tested. One representative experiment out of three is shown with s.e.m calculated from triplicate cultures. Three independent clones of each type were tested with similar results the STAT-recruiting site of the IL-9 receptor (in the IC98 IL-9R mutant) resulted in a 50-fold decreased sensitivity to IL-9, although high concentrations of IL-9 could still induce maximal proliferation. An important STAT5-target gene for this activity is pim-1 (Nosaka et al., 1999; Demoulin et al., 2000b) . We show here that the MAPK pathway is not involved in pim-1 regulation. Further studies will aim at identifying the genes that are regulated by this pathway. Growth stimulation by IL-9 may be mediated by three parallel signal transduction pathways: JAK/STAT, IRS2/PI-3 kinase and the MAPK cascade. A similar model might be valid for IL-4 too, as suggested by the effect of PD98059 (Figure 3) . It is more difficult to test this hypothesis by using IL-4R mutants as SHC, IRS2 and, to some extent, STAT6 are interacting with the same IL-4R docking site, which is required for proliferation (Keegan et al., 1994) .
Taken together, in contrast with previous reports, we show that the MAPK pathway can be activated transiently by IL-9 in hematopoietic cells, and contributes to growth stimulation in synergy with other pathways.
Materials and methods
Cell culture and reagents IL-9 and IL-3 were produced and purified in our laboratory from baculovirus-infected cell supernatant and CHO cells, respectively. IL-4 was purchased from R&D systems (Minneapolis, MN, USA). TS1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco/BRL, Merelbeke, Belgium) containing 10% fetal bovine serum (FBS) (Gibco/ BRL), nonessential amino acids, 5.5 Â 10 À4 m 2-mercaptoethanol (Gibco/BRL), and 100 U/ml of murine IL-9. Ba/F3, 32D and MC9 cells were grown in the same medium in the presence of 100 U/ml of murine IL-3. Ba/F3-hIL9R and 32D-hIL9R were described in previous reports (Demoulin et al., 2000a, b) . TS1-hIL9R, -IC98 and -IC44 were generated by puromycin Figure 5 IL-9 induces pim-1 expression independently of ERK activation. Ba/F3-hIL9R cells were starved for 6 h, pretreated with PD98059 as indicated, and stimulated for 2 h with human IL-9 or murine IL-3 (100 U/ml). Total RNA was extracted from 10 7 cells and analysed by Northern blot (10 mg/lane) with either a pim-1 or a b-actin probe, as described (Demoulin et al., 2001) Figure 6 IL-4 and IL-9 induce phosphorylation of SHC. Cells (25 Â 10 6 ) were starved for 6 h and stimulated for 5 min (a) or 10-30 min (b) with the indicated cytokine (250-1000 U/ml). GAB2 or SHC were immunoprecipitated from lysates as described in Materials and methods, and analysed by Western blot with 4G10 antiphosphotyrosine antibody. Blots were reprobed with anti-GAB2 or anti-SHC antibodies. A representative experiment out of three is shown selection (3 mg/ml) of cells electroporated with the corresponding hIL-9R cDNAs inserted into pEF-BOS-puro, as described (Demoulin et al., 1996) . Receptor expression was checked by flow cytometry as described (Demoulin et al., 1996) , and found similar in all bulk populations that were used. Ba/F3-hIL9R-M-RAS and -M-RAS-asn27 were obtained by electroporating M-RAS wild-type or dominant-negative construct into a Ba/ F3-hIL9R clone. Three clones of each type were selected with puromycin. Thymidine incorporation assays were performed as described (Demoulin et al., 1996) .
Western blots and inhibitor treatment
Cells were washed, resuspended in complete medium without cytokine, and incubated for 6 h at 371C. Cells were stimulated in the same medium (10 6 cells/ ml), centrifuged and resuspended in 250 ml of Laemmli buffer (BioRad, Nazareth, Belgium). A volume of 25 ml (10 5 cells) was loaded on 8% precast SDS-PAGE (Novex, Groningen, The Netherlands) and analysed by Western blot using antibodies specific for phosphorylated ERK1/2, MEK1/2, p90/RSK, STAT3 or STAT5 (1/1000, New England Biolabs, Beverly, MA, USA). For ERK1/2, we obtained the same results with the polyclonal and the E10 monoclonal antibodies (New England Biolabs). Anti-M-RAS antibody were described previously (Louahed et al., 1999) . They were visualized by ECL (Amersham, Roosendaal, The Netherlands), and quantified on a Kodak Imager ccd camera. Blots were reprobed with anti-b-actin antibodies (Sigma, S Louis, MO, USA) or anti-ERK2 antibodies (C-14, Santa Cruz) as a loading control. In some experiments, PD98059 was added for 1 h before stimulation (Biomol, Plymouth Meeting, PA, USA). Each Western blot experiment was repeated two to four times with similar results.
Immunoprecipitation
TS1 and Ba/F3-hIL9R cells were washed and cytokine-starved for 6 h. In total, 25 Â 10 6 cells were stimulated with IL-9 or IL-4 (100 U/ml) for 10-30 min, washed and resuspended in modified RIPA buffer (1% NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 50 mm Tris pH 8, 150 mm NaCl, 1 mm EDTA, 1 mm sodium vanadate, 1 mm NaF and protease inhibitor cocktail (Roche)). Lysates were homogenized by five passages through a 20-gauge needle, incubated for 30 min on ice, and centrifuged (13 000 g). Anti-SHC polyclonal antibodies (2.5 mg, Transduction Laboratories, Lexington, KY, USA), anti-GAB2 or anti-IRS2 antiserum (4 ml, Upstate Biotechnology Inc., Lake Placid, NY, USA) were added to supernatant and incubated overnight at 41C. Lysates were then incubated with protein-A-agarose for 2 h. Beads were washed, resuspended in Laemmli sample buffer (25 ml, BioRad) and boiled. Proteins were separated in an 8% SDS-PAGE gel (Novex) and analysed by Western blot using 1 mg/ml of antiphosphotyrosine 4G10 (Upstate Biotechnology Inc.) or anti-SHC monoclonal antibodies (Transduction Laboratories). Detection was performed by chemiluminescence (ECL, Amersham).
ERK2 kinase assay
TS1 cells were extensively washed, resuspended in medium for 6 h, and stimulated with IL-4 (10 ng/ml) or IL-9 (500 U/ml) for 10 min (2 Â 10 7 cells/5 ml). Cells were pelleted and resuspended for 30 min in 1 ml ice-cold RIPA buffer (1% NP-40, 0.1% sodium deoxycholate, 50 mm Tris pH 8, 150 mm NaCl, 1 mm EDTA, 2 mm sodium vanadate, 1 mm NaF and protease inhibitor cocktail (Boeringher)). Lysates were centrifuged for 20 min at 20 000 g. ERK2 was immunoprecipitated from supernatants with anti-ERK2 antibodies (C14, 2 mg, Santa Cruz Inc., Santa Cruz, CA, USA) for 1 h at 41C. Protein-Aagarose (20 ml, Gibco-BRL) was added for 1 h. Beads were washed twice with RIPA buffer, and twice with kinase buffer (20 mm HEPES, pH 7.2, 5 mm MgCl 2 , 1 mm EGTA, 2 mm dithiothreitol, 0.5 mm sodium vanadate). Beads were incubated with 20 ml reaction mix (g-32 P-ATP 10 mCi (50 mm) (Amersham), bovine myelin basic protein 1 mg/ml (Upstate Biotechnology Inc.), in reaction buffer) for 20 min at 301C. Reaction was stopped with 25 ml sample buffer, boiled for 3 min and loaded on 14% SDS-PAGE gels (Novex). Proteins were transferred onto nitrocellulose. Radioactivity corresponding to myelin basic protein (720 kDa) was quantified by Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). s.d. was calculated from duplicates.
